Exploring Three High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 1.6% drop, yet it has seen a significant 15% rise over the past year, with earnings expected to grow by 16% annually. In this context of fluctuating market conditions and promising growth forecasts, identifying high-growth tech stocks involves assessing their potential for innovation and scalability within this dynamic landscape.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating Marker Therapeutics 61.33% 65.71% ★★★★★★ Palantir Technologies 27.02% 31.25% ★★★★★★ Sandisk 30.23% 46.19% ★★★★★★ Reddit 22.20% 27.96% ★★★★★★ Gorilla Technology Group 54.35% 95.02% ★★★★★☆ Tenaya Therapeutics 58.52% 60.10% ★★★★★☆ Zscaler 15.93% 48.88% ★★★★★☆ Duos Technologies Group 53.76% 155.11% ★★★★★☆ Procore Technologies 12.08% 99.98% ★★★★★☆ KVH Industries 25.44% 135.75% ★★★★★☆

Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Gyre Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of $655.63 million.

Operations: Gyre Therapeutics specializes in small-molecule drugs targeting organ fibrosis, generating revenue primarily from its Gyre Pharmaceuticals segment, which reported $116.59 million. The company's focus on anti-inflammatory and anti-fibrotic treatments underpins its business model.

Gyre Therapeutics, a player in the high-growth sector of biotechnology focusing on liver fibrosis treatments, has shown promising developments with its lead product Hydronidone (F351). Recently achieving priority review status in China for its innovative approach to treating chronic hepatitis B-induced liver fibrosis, this designation could expedite the drug's market entry. Financially, Gyre reported a 10.2% increase in annual revenue to $116.59 million but faced a net income drop to $5.03 million from $12.09 million previously, reflecting investment back into R&D and market expansion efforts. The company's strategic merger with Cullgen Inc., valued at approximately $300 million, aims to bolster its research capabilities and expand its therapeutic portfolio, setting a robust foundation for future growth despite current earnings volatility.

Unlock comprehensive insights into our analysis of Gyre Therapeutics stock in this health report. Understand Gyre Therapeutics' track record by examining our Past report.GYRE Earnings and Revenue Growth as at Mar 2026

Clearfield

Simply Wall St Growth Rating: ★★★★☆☆

Story Continues

Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products both in the United States and internationally with a market cap of $396.99 million.

Operations: With a market cap of $396.99 million, Clearfield generates revenue primarily from its fiber management, protection, and delivery products, amounting to $154.78 million.

Clearfield's recent strategic initiatives and financial performance underscore its adaptability in the high-growth tech sector. With a 15.3% annual revenue growth, the company outpaces the US market average of 10.4%, reflecting robust demand for its offerings like the NOVA Platform, designed to enhance network scalability and manageability in diverse environments. This innovation is critical as data center fiber demand grows, driven by trends towards higher bandwidth solutions like 100G optics. Moreover, Clearfield's earnings are expected to surge by an impressive 60.8% annually, significantly ahead of broader market growth rates (15.6%), showcasing its potential for profitability despite a challenging competitive landscape marked by substantial insider selling recently.

Click here and access our complete health analysis report to understand the dynamics of Clearfield. Learn about Clearfield's historical performance.CLFD Earnings and Revenue Growth as at Mar 2026

Invivyd

Simply Wall St Growth Rating: ★★★★★☆

Overview: Invivyd, Inc. focuses on researching, developing, commercializing, and selling antibody therapies to prevent and treat viral infectious diseases in the United States with a market cap of $440.85 million.

Operations: Invivyd, Inc. generates revenue primarily through the discovery, development, and commercialization of antibody-based solutions, totaling $53.43 million.

Invivyd's recent operational and strategic developments underscore its potential in the biotech sector, despite facing significant challenges. In 2025, the company more than doubled its revenue to $53.43 million from $25.38 million the previous year, reflecting a remarkable growth trajectory. However, concerns arise as its auditor expressed doubts about its ability to continue as a going concern. The appointment of Dr. Michael Mina as Chief Medical Officer could inject new vigor into Invivyd’s R&D efforts; his extensive background in viral immunology and public health enhances the company's scientific credibility particularly in developing treatments like VYD2311 for COVID-19 prevention. This move aligns with Invivyd’s focus on innovative monoclonal antibody therapies, which could be pivotal given the ongoing adjustments in public health strategies towards managing viral diseases.

Delve into the full analysis health report here for a deeper understanding of Invivyd. Evaluate Invivyd's historical performance by accessing our past performance report.IVVD Earnings and Revenue Growth as at Mar 2026

Where To Now?

Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 70 more companies for you to explore.Click here to unveil our expertly curated list of 73 US High Growth Tech and AI Stocks. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Contemplating Other Strategies?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GYRECLFD and IVVD.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments